BioSpecifics Technologies Corp (BSTC) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS

BioSpecifics Technologies Corp (NASDAQ:BSTC) issued its earnings results on Friday. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.36 by $0.01, Bloomberg Earnings reports. BioSpecifics Technologies Corp had a net margin of 43.06% and a return on equity of 20.65%. The firm had revenue of $6.52 million during the quarter, compared to analysts’ expectations of $6.59 million.

Shares of BioSpecifics Technologies Corp (BSTC) opened at $43.63 on Friday. The company has a market cap of $313.66, a price-to-earnings ratio of 27.44 and a beta of 1.64. BioSpecifics Technologies Corp has a 52-week low of $41.95 and a 52-week high of $58.79.

TRADEMARK VIOLATION NOTICE: “BioSpecifics Technologies Corp (BSTC) Posts Quarterly Earnings Results, Beats Estimates By $0.01 EPS” was first posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another domain, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The legal version of this story can be accessed at https://www.themarketsdaily.com/2017/11/12/biospecifics-technologies-corp-bstc-posts-quarterly-earnings-results-beats-estimates-by-0-01-eps.html.

Several research analysts recently issued reports on the stock. BidaskClub cut shares of BioSpecifics Technologies Corp from a “sell” rating to a “strong sell” rating in a report on Friday, August 18th. HC Wainwright set a $72.00 target price on shares of BioSpecifics Technologies Corp and gave the stock a “buy” rating in a report on Thursday, August 10th. Finally, Zacks Investment Research raised shares of BioSpecifics Technologies Corp from a “sell” rating to a “hold” rating in a report on Tuesday, October 10th.

BioSpecifics Technologies Corp Company Profile

BioSpecifics Technologies Corp. is a biopharmaceutical company involved in the development of an injectable collagenase clostridium histolyticum for multiple indications. The Company has a development and license agreement with Endo Global Ventures, a Bermuda unlimited liability company (Endo Global Ventures), an affiliate of Endo International plc (Endo), for injectable collagenase for marketed indications and indications in development.

Earnings History for BioSpecifics Technologies Corp (NASDAQ:BSTC)

Receive News & Ratings for BioSpecifics Technologies Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply